Reopia Optics, Inc.

Nearsightedness, or myopia, is exploding around the world. Unless the trend is stopped, 50% of the world’s population will be myopic by the year 2050. Ten percent of these myopes will be at high risk for blinding complications. In the past, children played outdoors for hours, whereas today they spend hours each day on smart phones and other digital display devices (whether indoors or outdoors). Reopia Optics is developing patented eyeglasses that will prevent the myopia pandemic.

We have strong patent protection, prototypes for animal studies to be conducted in Singapore, initial interest from strategics, and an exceptional Scientific Advisory Board.

All children at risk for developing myopia.

The worldwide pandemic of nearsightedness will lead to tremendous expenses and impact on quality of life unless we intervene. Reopia Optics spectacles can safely be worn by young children to prevent the development of myopia.

Spectacles are easier and safer, especially in children from 4-12 years old, than alternatives such as contact lenses or eye drops.

There are spectacles, eye drops, and contact lenses. Among spectacles, we have unique, patent protected technology that we anticipate will deliver superior results.

Reopia’s unique, patented spectacles are the only solution to deliver a powerful signal to the retina that suppresses myopic progression through the novel use of micro-lens arrays in combination with well defined, high contrast patterns, creating a targeted, augmented retinal image.

Selling Reopia spectacles to patients.

We will seek a distribution partner likely in the vision care space.

IP, Pre-clinical studies, technology optimization, clinical study.

The Convertible Note will convert into equity at the value determined by terms of our first equity round, without discount or cap, but offering interest and a warrant.

New competitors enter the field with new technology.

Selected and completed the Health Wildcatters accelerator in Dallas TX.

Selected to present at OIS Myopia conference - https://ois.net/ois-myopia-management-showcase-2021/ .

16/052,407, 2019-0038123

16/366,972, US10,921,612

16/583,093, 2020-0089023

We are also filing a patent in China through the PCT